期刊文献+

羟基喜树碱联合顺铂治疗28例晚期鼻咽癌的近期疗效分析 被引量:1

Hydroxycamptothecin Combined with Cisplatin in the Treatment of 28 Patients of Advanced Nasopharyngeal Cancer
在线阅读 下载PDF
导出
摘要 目的 :观察羟基喜树碱 (HCPT ,拓僖 )联合顺铂 (DDP)治疗晚期鼻咽癌 (NPC)的近期疗效及不良反应。方法 :应用HP方案治疗晚期NPC 2 8例。HCPT(6mg/m2 d1~ 3 )加入NS 2 0mL缓慢滴注 ,DDP(2 5mg/m2 d1~ 3 )加入NS 5 0 0mL中滴注 ,每 3周重复 ,至少治疗 2个周期。结果 :本组完全缓解 3例 ,部分缓解 12例 ,稳定 10例 ,进展 3例 ,总有效率 5 3. 6 %。主要毒副反应为WBC减少、恶心呕吐、腹泻、脱发。其中Ⅲ~Ⅳ度WBC减少发生率 35 . 7% ,Ⅱ~Ⅲ度恶心、呕吐 4 2 . 9% ,腹泻2 5 . 0 % ,脱发 35. 7%。结论 :HCPT联合DDP治疗晚期NPC疗效好 ,且毒性可以耐受。 Objective: To evaluate the efficacy and adverse reactions of hydroxycamptothecin(HCPT)combined with cisplatin(DDP )in the treatment of advanced nasopharyngeal cancer(NPC). Methods: Twenty-eight patients with advanced NPC were injected HCPT(6 mg/m2 d 1~3 )with normal saline of 20 mL and DDP(25 mg/m2 d 1~3)wit h normal saline of 500 mL every 3 weeks.The treatment was repeated from 2 to 6 cyc les. Results: The total effective rate was 53.6% with complete remission of 3 c a ses and partial remission of 12 cases. Grade 3/4 leucopenia was occurre d in 32. 1% patients, grade 2/3 nausea and vomiting was 42.9%, diarrhea was 25.0%, al opecia was 35.7%. Conclusion: HCPT combined with DDP is a safe and effec tive method for advanced NPC.
出处 《汕头大学医学院学报》 2005年第1期27-28,共2页 Journal of Shantou University Medical College
关键词 治疗 联合 HCPT 晚期鼻咽癌 近期疗效 DDP 羟基喜树碱 结论 目的 周期 hydroxycamptothecin cisplatin advanced naso pharyngeal cancer combined chemotherapy
  • 相关文献

参考文献6

二级参考文献18

  • 1管忠震.鼻咽癌化学治疗的概况[J].癌症,1989,8(2):120-121. 被引量:66
  • 2凌扬.治疗非小细胞性肺癌的药物[J].新药与临床,1995,14(5):286-288. 被引量:2
  • 3[1]Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase Ⅲ trial of Southeastern Cancer Study Group [J]. J Clin Oncol, 1992, 10(2): 282-291.
  • 4[2]Fukuoka M, Furuse K,Saijo N,et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer [J]. J Natl Cancer Inst,1991,83(12): 855-861.
  • 5[3]Shepherd FA, Evans WK, MacCormick R, et al. Cyclophosphamide, doxorubicin, and vincristine in etoposide and cisplatin-resistant small cell lung cancer [J]. Cancer Treat Rep, 1987, 71(10): 941-944.
  • 6[4]Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease [J]. J Clin Oncol, 1997, 15(5): 2090-2096.
  • 7[5]Von-Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin,and vincristine for treatment of recurrent small cell lung cancer [J]. J Clin Oncol, 1999, 17(2): 658-667.
  • 8[6]Perez-Soler R, Glisson BS, Lee JS, et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan [J]. J Clin Oncol, 1996, 14(10): 2785-2790.
  • 9[2]Au E, Ang PT. Aphase I trial of 5-fluorouracil and cisplatinum in recurrent or matastatic nasopharyngeal carcinoma. Ann Oncol,1994,5(1):87-89.
  • 10[4]Hsiang YH,Hertzberg R,Hecht S,et al.camptothecin indnces Protein-linked DNA breaks via mammalian DNAtopoisomerase I J Med Chen,1985,260(27):14 873-14878.

共引文献59

同被引文献12

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部